The Depression and Anxiety List (Dal): Description and Reliability

Huyser, Jochanan; Jonghe, Frans de; Sno, Herman N.; Schalken, H. F. A.

doi:10.1002/(sici)1234-988x(199604)6:1<5::aid-mpr137>3.3.co;2-g

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonresponsive patients receiving antidepressants were therefore offered complementary psychodynamic supportive psychotherapy, whereas Downloaded by [217.122.252.24] at 02:24 20 June 2014 Depression with or without dysthymia. The DSM diagnosis was assessed by means of a semi-structured interview (Huyser, De Jonghe, Sno, & Schalken, 1996). A further inclusion criterion was a certain score on the 17-item Hamilton Depression Rating Scale (HAM-D; Hamilton, 1967).…”

Section: Goals Of the Five Rctsmentioning

confidence: 99%

Growing Evidence for Psychodynamic Therapy for Depression

Dekker¹,

Hendriksen

Kool

et al. 2014

Contemporary Psychoanalysis

Self Cite

View full text Add to dashboard Cite

Abstract. Psychodynamic therapy (PT) for depression is the least examined treatment method for depression, compared to cognitive-behavioral therapy (CBT) and interpersonal therapy. This article, consisting of five randomized clinical trials of short psychodynamic supportive psychotherapy (SPSP) conducted over the last 25 years in Amsterdam, will review the trial results to provide answers to the question about which role SPSP can play in the treatment of depression. The researchers conclude that it is justified to qualify SPSP an empirically supported therapy form of PT for depression. In particular, adding SPSP to pharmacotherapy yields better results than pharmacotherapy by itself. Adding medication to SPSP may have a significant added value, but it is not as large as in the first comparison. The results also confirm no difference in efficacy between CBT and SPSP.

show abstract

Section: Goals Of the Five Rctsmentioning

confidence: 99%

Growing Evidence for Psychodynamic Therapy for Depression

Dekker¹,

Hendriksen

Kool

et al. 2014

Contemporary Psychoanalysis

Self Cite

View full text Add to dashboard Cite

show abstract

The Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties

Guidi

Fava

Bech

et al. 2010

Psychother Psychosom

View full text Add to dashboard Cite

Background: A comprehensive assessment of the wide spectrum of depressive symptomatology, particularly in its subclinical forms, is lacking in standard rating scales. There is also an emerging need for instruments that can detect small differences in therapeutic studies and have good sensitivity. The purpose of this paper is to review the clinimetric characteristics of Paykel’s Clinical Interview for Depression (CID) and to examine the results of the studies in which the interview has been used. Methods: Published reports which involved the use of the CID were identified by searching the following electronic databases: Medline, PsychINFO, EMBASE, and Web of Science. A manual search of the literature was also performed. Results: The initial strategies yielded 169 published reports for potential inclusion in the review: 98 are discussed here. The CID has been used extensively in a variety of studies, including descriptive studies, classification by means of factor analysis and cluster analysis, and predictor variables of response to treatment or relapse. The CID has also been used as an outcome measure in several controlled clinical trials and follow-up studies of pharmacotherapy and psychotherapy of affective disorders. It has been shown to be valid and reliable, to discriminate depressives from controls, or different subgroups of depressed patients, and to reflect changes during the course of treatment, particularly when individual symptoms are considered. Conclusions: Evidence from these studies highlights the utility of the CID in clinical research and practice. Its clinimetric characteristics, particularly the broad evaluation of affective symptomatology and the sensitivity to change, make it an instrument of choice in therapeutic trials.

show abstract

Triiodothyronine Addition to Paroxetine in the Treatment of Major Depressive Disorder

Appelhof¹,

Brouwer²,

Dyck

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

There is evidence that thyroid hormone T3 increases serotonergic neurotransmission. Therefore, T3 addition to antidepressants may improve treatment response in major depression. In nonrefractory depression, T3 addition to tricyclic antidepressants indeed accelerates treatment response. Current therapeutic practice favors selective serotonin reuptake inhibitors. This is the first study to investigate the efficacy of T3 addition to paroxetine in major depression. One hundred thirteen patients with major depressive disorder were randomly assigned to 8 wk of double-blind outpatient treatment with low-dose T3 (25 microg), high-dose T3 (25 microg twice daily), or placebo in addition to paroxetine 30 mg daily. A total of 106 patients started treatment and were included in the outcome analysis. Response rate after 8 wk (reduction of Hamilton Rating Scale for Depression score > or = 50%) was 46% in all three treatment arms (P = 0.99). T3 addition did not accelerate clinical response to paroxetine, nor was an effect of T3 found when only women were analyzed. Patients on T3 addition reported more adverse events than patients on placebo comedication. In conclusion, these results do not support a role for T3 addition to selective serotonin reuptake inhibitors in the treatment of nonrefractory major depressive disorder. On the contrary, more adverse reactions occurred in T3-treated patients.

show abstract

The Depression and Anxiety List (Dal): Description and Reliability

Cited by 3 publications

References 15 publications

Growing Evidence for Psychodynamic Therapy for Depression

Growing Evidence for Psychodynamic Therapy for Depression

The Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties

Triiodothyronine Addition to Paroxetine in the Treatment of Major Depressive Disorder

Contact Info

Product

Resources

About